Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly results. The firm keeps an Overweight rating on the shares.

) has been revised to $8.01 / share. This is an increase of 22.34% from the prior estimate of $6.55 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. If you are wondering whether Gilead Sciences stock still offers value at current levels, it ...

Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public offering at $21.00 ...

Ten financial analysts have updated their short term price target for Exact Sciences, the company that developed Cologuard, according to an MFI report. The company’s short term price target estimate ...